Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
neuropathy on her right jawline extends to the back of her hear and she notices it on her scalp as well; This serious case was reported by a consumer via call center representative and described the occurrence of neuropathy in a female patient who received Herpes zoster (Shingrix) for prophylaxis. In FEB-2026, the patient received the 1st dose of Shingrix. In MAR-2026, less than 2 months after receiving Shingrix, the patient experienced neuropathy (Verbatim: neuropathy on her right jawline extends to the back of her hear and she notices it on her scalp as well) (serious criteria GSK medically significant). The outcome of the neuropathy was not resolved. It was unknown if the reporter considered the neuropathy to be related to Shingrix. The company considered the neuropathy to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 17-APR-2026 The patient who had received her first dose of Shingrix two months earlier. The batch number was not provided upon follow up with the reporter.; Sender's Comments: A case of Neuropathy peripheral (not meeting BC criteria), less than 2 months after receiving 1st dose of Shingrix in a female patient. Case lacks further information on exact time to onset, medical history, concurrent conditions, concomitant medications and relevant laboratory results. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.